Global Information
회사소개 | 문의

혈우병 A : 파이프라인 리뷰

Hemophilia A - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 05월 상품 코드 232826
페이지 정보 영문 182 Pages
가격
US $ 2,000 ₩ 2,257,600 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,515,200 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,772,800 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


혈우병 A : 파이프라인 리뷰 Hemophilia A - Pipeline Review, H1 2018
발행일: 2018년 05월 페이지 정보 : 영문 182 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

혈우병 A는 X염색체 연쇄 열성 결손증으로 혈액 응고 제VIII 인자(FVIII)의 부족에 의해 발생하며, 유전 또는 자연 돌연변이에 의해 발병합니다. FVIII 활동의 수준에 따라 혈우병 환자는 멍이 쉽게 생기고 외상을 입어도 충분히 응고하지 않으며, 중증 혈우병은 자발성 출혈을 수반합니다. 증상은 통증과 부종을 수반하는 관절내 출혈 및 혈뇨·혈변, 멍, 소화관과 요로 출혈, 코피, 절상 및 발치, 수술시 계속되는 출혈, 돌발성 출혈 등을 들 수 있습니다.

혈우병 A(Hemophilia A) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

혈우병 A 개요

치료제 개발

  • 파이프라인 제품;개요
  • 기업별 파이프라인
  • 대학/연구기관에서 개발된 파이프라인
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • Alnylam Pharmaceuticals Inc
  • Amarna Therapeutics BV
  • Apitope International NV
  • Bayer AG
  • BioMarin Pharmaceutical Inc
  • Bioverativ Inc
  • Catalyst Biosciences Inc
  • Chugai Pharmaceutical Co Ltd
  • CSL Ltd
  • DBV Technologies SA
  • Dimension Therapeutics Inc
  • Emergent BioSolutions Inc
  • EpiVax Inc
  • Expression Therapeutics LLC
  • Green Cross Corp
  • Idogen AB
  • Immusoft Corp
  • Lentigen Technology Inc
  • mAbxience SA
  • Novo Nordisk A/S
  • OPKO Biologics Ltd
  • Pangen Biotech Inc.
  • Pfizer Inc
  • Pharming Group NV
  • Promethera Biosciences SA
  • rEVO Biologics Inc
  • Sangamo Therapeutics Inc
  • Shire Plc
  • SK Chemicals Co Ltd
  • Spark Therapeutics Inc
  • UniQure NV
  • XL-protein GmbH

약제 개요

휴지 상태의 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.07.24

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H1 2018, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or aris from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 10, 7, 4, 24, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Hemophilia A - Overview
  • Hemophilia A - Therapeutics Development
  • Hemophilia A - Therapeutics Assessment
  • Hemophilia A - Companies Involved in Therapeutics Development
  • Hemophilia A - Drug Profiles
  • Hemophilia A - Dormant Projects
  • Hemophilia A - Discontinued Products
  • Hemophilia A - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hemophilia A, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Hemophilia A - Pipeline by Alnylam Pharmaceuticals Inc, H1 2018
  • Hemophilia A - Pipeline by Amarna Therapeutics BV, H1 2018
  • Hemophilia A - Pipeline by Apitope International NV, H1 2018
  • Hemophilia A - Pipeline by Bayer AG, H1 2018
  • Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H1 2018
  • Hemophilia A - Pipeline by Bioverativ Inc, H1 2018
  • Hemophilia A - Pipeline by Casebia Therapeutics, H1 2018
  • Hemophilia A - Pipeline by Catalyst Biosciences Inc, H1 2018
  • Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
  • Hemophilia A - Pipeline by CSL Ltd, H1 2018
  • Hemophilia A - Pipeline by DBV Technologies SA, H1 2018
  • Hemophilia A - Pipeline by EpiVax Inc, H1 2018
  • Hemophilia A - Pipeline by Expression Therapeutics LLC, H1 2018
  • Hemophilia A - Pipeline by GC Pharma, H1 2018
  • Hemophilia A - Pipeline by ID Pharma Co Ltd, H1 2018
  • Hemophilia A - Pipeline by Idogen AB, H1 2018
  • Hemophilia A - Pipeline by Immusoft Corp, H1 2018
  • Hemophilia A - Pipeline by Innovare R & D SA De CV, H1 2018
  • Hemophilia A - Pipeline by LFB SA, H1 2018
  • Hemophilia A - Pipeline by mAbxience SA, H1 2018
  • Hemophilia A - Pipeline by Novo Nordisk AS, H1 2018
  • Hemophilia A - Pipeline by Okklo Life Sciences BV, H1 2018
  • Hemophilia A - Pipeline by OPKO Biologics Ltd, H1 2018
  • Hemophilia A - Pipeline by Pangen Biotech Inc., H1 2018
  • Hemophilia A - Pipeline by Pfizer Inc, H1 2018
  • Hemophilia A - Pipeline by Pharming Group NV, H1 2018
  • Hemophilia A - Pipeline by Promethera Biosciences SA, H1 2018
  • Hemophilia A - Pipeline by Sangamo Therapeutics Inc, H1 2018
  • Hemophilia A - Pipeline by Shire Plc, H1 2018
  • Hemophilia A - Pipeline by Sino Biopharmaceutical Ltd, H1 2018
  • Hemophilia A - Pipeline by SK Chemicals Co Ltd, H1 2018
  • Hemophilia A - Pipeline by Spark Therapeutics Inc, H1 2018
  • Hemophilia A - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2018
  • Hemophilia A - Pipeline by UniQure NV, H1 2018
  • Hemophilia A - Pipeline by XL-protein GmbH, H1 2018
  • Hemophilia A - Dormant Projects, H1 2018
  • Hemophilia A - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Hemophilia A, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Targets, H1 2018
  • Number of Products by Stage and Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research